Jeff. Thanks,
to integrating products FIRDAPSE strategy and enhancing expanding on commercial Our clinical all FIRDAPSE the to acquired regulatory patent Vamorolone organization. access LEMS for and maximize to newly focus its into patients, development Catalyst to continues FYCOMPA the state and potential
to of daily submitted dose NDA indicated would for to a the this dose. per discuss I XXX development has to XX First, change now day to milligrams maximum like milligrams the per efforts maximum FIRDAPSE Catalyst FDA increase to supplementary our from the day.
assurance of of any significant XXXX. review can approval there the this the Catalyst of of submission, be anticipates completion quarter or issues While buying no sNDA acceptance first agency's with in the
Currently, daily we for FDA to XXX there LEMS per our for with this milligrams are that XXX dosage physician supplement, of on indicated year, will dose patient's of those strategy believe justify Other XXX of dosage who at to current their submission patients, milligram the acceptable a with approved, daily worked our pharmacy are a an dose. maximum maximum basis milligram FIRDAPSE XX the patients optimize increase providers a already May C And meeting Based have expressed and help constitutes desire the seeking number insurance daily doses being after if higher therapy. the milligrams Type physicians this patients. treated the on and their FIRDAPSE. to day to of in
that Regarding in the found of expansion, to no FIRDAPSE We about PMDA will type to approval the the that we be that XX estimate months partner agency in our be pharmaceuticals take submission devices this our by will by their typically XX Pharma a can such global NDA of within to are about this or there Japan. X,XXX medical XXXX. Japan, X,XXX but LEMS month Submissions submit anticipate DyDo end assurance and there period. review for patients PMDA,
secondarily only rights is approved first with receptor other treat approved without U.S. generalized of with are to perampanel, tonic as who an with inhibitor. which FYCOMPA the seizures with acquired or or antagonist and partial epilepsy, or Catalyst of four XX-years who medicines treat is primary reported, older. AMPA anti-seizure medication FYCOMPA and people onset previously As seizures and seizures to or years are in or age generalized age to chronic epilepsy older people
subsequently showed seizures As previously presentation reported to perampanel epilepsies. generalized with quarter, hold clinical that reduce the rare FYCOMPA and continues perampanel published further countries at and documenting were the and [ASI] These lennox-gastaut the were results who different article March, published quarter history range with effectively in regions that an of with the in four virtually. syndrome on and the or abstracts epilepsy the patients genetic detailed this behavioral a underage and rights the in from second psychiatric those four the published FYCOMPA eight has epilepsy Boston are In patients, sponsored diverse outside across in events, independent of including highlighting patients of presented AAN focal by -- abstracts to both in (ph), meeting XXXX and U.S. core patients studies The to seizures linked uses researchers both LGS.
summarizing and month, FYCOMPA first studies safety this in patients. papers published Just researchers of pediatric three efficacy the of
on oral real study FYCOMPA efficacy focusing perampanel the on global epilepsy. FYCOMPA, group extension alternative Second, patients. a safety to by and generalized third, age And when a pooled focal study use of and treating an world as IV epilepsy and
whole, great rare highlights interest academic unique treat evolution mechanism its Taken FYCOMPA’s activity the refractory this an treatment area ongoing rare epilepsies as a to in all and Catalyst. and field variety of toward epilepsies medicine potential epilepsy interest of research action, the precision of to in and identification of and of the a
potential Santhera Vamorolone of studies for with the a reduction our territory. Duchenne like steroid DMD of Vamorolone offering received XX, need DMD in-licensing has demonstrated important in granted and a I the been Muscular to anti-inflammatory bone and is clinical corticosteroid Vamorolone associated drug recent by significant has FDA action growth, American designations unmet discuss promising an Next, Vamorolone fast for track address October in patients. for XXXX. for health, side would efficacy dissociative treatment of Dystrophy and or DMD to effects date orphan the PDUFA medical and from North behavior, benefits treatment of
this occurring a genetic most and the rare survival patients of increase also that tragic has XX,XXX about is continue is FDA The designation. is is treatments in available genetic pediatric an skeletal exclusively like gets the disease male worse increasing to DMD gradually prevalence as heart condition XXX dystrophy. and is granted that muscle is newborns common It the males. gene to the a DMD time and about each all disorder from and form to defect of virtually suffering excellent XX,XXX weaken The quickly the disease. muscular Vamorolone with excellent almost diseases patients dystrophin year. rare affects
the Approximately therapies are XX% XX% treatments other other one like approved exon patients with amenable of corticosteroids. needing to of the the skipping
other treatments to mother, exon DMD happen treatments inherited. but due are carrier, the and at like skipping majority inherited mutations the The need gene some However, cases of genetic defective even who treated her continue that cases the to are spontaneous with patients new from are approximately of corticosteroids level. XX% is randomly not
Muscular month the that the use treatment. during of for Project report spanning is taking reasons. a of reported and registry a safety corticosteroid to XX% use may just safer remainder of time Parent a diagnosis and X.X average earlier based corticosteroids The lead therapy. patients This routine on of and clinical years is on patients of in XX-years less may that age years, average therapy daily and was initiation X.X use of Vamorolone It diagnosis closer or be of to more anticipated is initiation basis, an X,XXX Dystrophy regular corticosteroids frequent this PPMD the for presumably taking with
with that functional receptor, omitted of research XX in thus system. it receptor apart the interaction with the anti-inflammatory sites at medications This approved hypothesized this [Indiscernible] type. position Vamorolone the glucocorticoid than Vamorolone data steroidal in it lacks and oxygen Vamorolone is is corticosteroids. corticosteroid This other makes altering a the it molecular better all profile five a clinical Earlier oxygen group this how functionality safety year published first-in-class drug ring difference for an sets meta-analysis a Vamorolone’s of interaction from other one steroid class. in have
Vamorolone deflazacort, of retardation, as growth but difference. mineralocorticoid agonist as of raising via this Furthermore, prednisone as system. atrophy models, and such anti-inflammatory numerous bone corticosteroids result angiotensin properties a receptor, and its of such steroid volume lacks the animal retains and medications, In effects side pressure renin the muscular blood morbidities act the as
In same the activity Vamorolone therapy. mineralocorticoid bot or antagonist contrast, in the summary eliminating Vamorolone eliminating which receptor, thus antagonism while mineralocorticoid in most has and effects, receptors. traditional activity, optimize of side mineralocorticoid eplerenone side may approved effects to its the binding anti-inflammatory In preclinical corticosteroid as the the spironolactone of steroidal potent are of and agonism models drugs, due glucocorticoid unique Vamorolone various or
starting potential Overall, has desirable the with to DMD need DMD medical a patient the an in options, profile unmet to current early for for differentiated standard-of-care an Vamorolone at treatment be important age. addressing comparison a
those treat on science expand life. to out patients LEMS the about the functional well-being patients that of that to ability for perception patients. and in maintain maintain Moving relationships neuromuscular, All medical muscle improving already treated to critical practices quality of provide the in order for found and the their MSLs to use liaisons, their with strength, healthcare are Catalyst the to patient's medical physician's FIRDAPSE testing education FIRDAPSE patients domains mobility. Oncologists these have LEMS are of our to build continuing or importance information patients by function, reach oncology to providers of
also epilepsy any FYCOMPA the real FYCOMPA. extensive published a and the Catalyst new team team have product providers available,, using MSL onboarded those and FYCOMPA. is I information The for healthcare prior reported, which all previously world with address information MSL that mature epilepsy may about to that director, and support their abstracts this has publications new mentioned. experience FYCOMPA will questions bring is physicians also treat data including and previously to As
treaters Catalyst a IEC in MSL minds AES epilepsy keep for as team Additionally, FYCOMPA FYCOMPA treatment. option and of conferences to potential attends epilepsy the order epilepsy like in
should area has Future and MSL With that the four new ongoing will the they due in of an DMD Catalysts be result that useful of stream Dystrophy, be in patients. disseminated developed to and information it treatment medical an of active continues be their doctors, unique specializing information in-licensing research Duchenne that the of implemented for be so updates programs Vamorolone, will of are medical to can mechanistic to Vamorolone. optimize provided adding will Vamorolone, to features Muscular as continue
to of support the years service healthcare diagnosis a provided in educational the of three CME hundreds provides for ongoing programs education various CME the a and of order utilized physician providers. period modules the Catalyst learning and of continuing medical treatment medical As tests have support development for formal CME of for over three aspects granted program healthcare their them or CME management Catalyst part maintenance of community has of each are past Over the are licenses. credit providers thousands be LEMS. CME program's toward of this quarter to time, of taking that
frequency we between In credit. due and a since CME appear that valuable LEMS. almost additional new over correlation taking additional quarter this CME healthcare the just the LEMS use taken short, XXXX, to providers months, are that test have part In oncology for to test education. program fourth ongoing based CME targeted medical associated sponsored cell of a of popular be was treat last and small with In the reported, mis-cancer of course four on programs treaters, these the oncologists XXX the cancer, their
CFO. At this our to time, I Alicia would over call turn Grande, like the to
